Loading your page…
Pharmaceutics
By Tao Wang, Keyun Tang, Fengrun Sun and 5 others.
Background/Objectives: Chronic neuropathic pain imposes a substantial burden on patients and society, and opioids are unsuitable for long-term use due to their addictive potential. To overcome this limitation, we encapsulated bupivacaine in PLGA nanoparticles to achieve sustained-release analgesia with reduced systemic toxicity.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
The analgesic efficacy was evaluated in rat models of chronic compression of the dorsal root ganglion (CCD) and chronic constriction injury (CCI). Nanoparticles were characterized using scanning electron microscopy (SEM) for morphology and size, and X-ray diffraction (XRD) for dispersion. In vivo electrophysiological recordings, including action potentials from DRG neuronal somata and compound action potentials in the sciatic nerve, were performed to investigate peripheral analgesic mechanisms, while plasma bupivacaine concentrations were measured by high-performance liquid chromatography (HPLC).
Bupivacaine nanoparticles significantly alleviated mechanical pain in both CCD and CCI rats, but had no effect on thermal pain. They selectively inhibited C-fiber conduction without affecting A-fibers. Importantly, plasma bupivacaine levels remained well below the corresponding toxic thresholds, indicating a favorable safety profile.
These findings suggest that bupivacaine-loaded PLGA nanoparticles represent a promising long-term therapeutic option for chronic neuropathic pain management.
Published in Pharmaceutics. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
